Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07253285 · ClinicalTrials.gov registry record · Phase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

A Phase 3 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.

Recruiting
Registry status
Phase 3
Development phase
460
Enrollment target
20
Study locations

NCT07253285 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 460 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07253285, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Novo Nordisk A/S.

RECRUITING
Registry status
Phase 3
Development phase
460 participants
Enrollment target
20
Study locations

Study Summary

This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants who get semaglutide in the main study will not take part in the extension study. If participants take part in the extension study, they will get either CagriSema or cagrilintide in this part of the study. Like all drugs, the study drugs may have side effects. The total time participants will be in the main study is about 1 year and 6 months. If participants take part in the extension study, the total time is about 4 years and 10 months.

Conditions Studied

Obesity Overweight

Interventions

  • DRUG Semaglutide
  • DRUG Cagrilintide
  • DRUG Placebo cagrilintide
  • DRUG Placebo semaglutide

Study Locations (20)

Georgia

  • Children's Healthcare Atlanta - Atlanta
  • Columbus Research Foundation - Columbus
  • Accel Research Sites-NeuroStudies - Decatur
  • Eastside Bariatric and Gen Surg - Snellville

Florida

  • Encore Medical Research LLC - Hollywood
  • Jacksonville Ctr for Clin Res - Jacksonville
  • Encore Medical Research of Weston - Weston

New York

  • UBMD Physicians Group - Pediatrics - Conventus - Buffalo
  • SUNY Upstate Medical Univ - Syracuse - Syracuse
  • Advantage Clinical Trials - The Bronx

Minnesota

  • University of Minnesota - Minneapolis
  • AES Minneapolis DRS - Richfield

California

  • Neighborhood Healthcare - Escondido

Idaho

  • Solaris Clinical Research - Meridian

Indiana

  • IU Health - Riley Physicians Endo-Diab - Indianapolis

Kansas

  • Cotton O'Neil Clinical Research Center - Topeka

Trial Details

FieldValue
Enrollment Target 460 participants
Start Date 2026-01-08
Est. Completion 2033-09-20
Phase Phase 3

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07253285

The ClinicalTrials.gov registry entry for NCT07253285 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (44% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Semaglutide is the first listed.

NCT07253285 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Georgia, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT07253285 about?

NCT07253285 is a clinical study titled "A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight". This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (...

What is the current status of trial NCT07253285?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2026-01-08. Estimated completion is 2033-09-20.

What conditions does trial NCT07253285 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT07253285?

The interventions under investigation include: Semaglutide (DRUG), Cagrilintide (DRUG), Placebo cagrilintide (DRUG), Placebo semaglutide (DRUG).

Who is sponsoring clinical trial NCT07253285?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07253285 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.